Form 13-F position report

CARDIOL THERAPEUTICS INC

Reported by MMCAP International Inc SPC

Company profile Manager portfolio Source filing
CRDL CUSIP 14161Y200 Manager CIK 0001304857
Latest reported change

Reported 15,598,560 shares, up 246,243 (1.6%) from the prior quarter.

Reported value -20.2%; share count 1.6% vs. the prior quarter.

Added
% of reported 13F value 1.4% This manager · Q2 2026
Shares 15,598,560 Quarter-end amount reported
Reported value $16,534,474 Fair value at quarter end
Consecutive quarters held 19 Through Q2 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q2 2026 Added 15,598,560 +246,243 (1.6%) 1.4% $16,534,474 2026-08-14
Q1 2026 Added 15,352,317 +15,143,367 (7247.4%) 1.79% $20,725,628 2026-05-15
Q4 2025 Reduced 208,950 -84,106 (-28.7%) 0.02% $199,297 2026-02-09
Q3 2025 Unchanged 293,056 0 (0.0%) 0.04% $313,570 2025-11-10
Q2 2025 Reduced 293,056 -489,569 (-62.6%) 0.05% $398,556 2025-08-06
Q1 2025 Reduced 782,625 -13,000 (-1.6%) 0.13% $758,990 2025-05-12
Q4 2024 Unchanged 795,625 0 (0.0%) 0.15% $1,018,400 2025-02-04
Q3 2024 Reduced 795,625 -128,500 (-13.9%) 0.22% $1,575,338 2024-11-12
Q2 2024 Reduced 924,125 -1,642,000 (-64.0%) 0.26% $1,866,732 2024-08-13
Q1 2024 Reduced 2,566,125 -387,175 (-13.1%) 0.6% $4,644,686 2024-05-09
Q4 2023 Unchanged 2,953,300 0 (0.0%) 0.49% $2,655,903 2024-02-12
Q3 2023 Unchanged 2,953,300 0 (0.0%) 0.76% $2,643,204,000 2023-11-13
Q2 2023 Reduced 2,953,300 -200,100 (-6.3%) 0.87% $2,628,437 2023-08-14
Q1 2023 Reduced 3,153,400 -200,000 (-6.0%) 0.3% $1,536,652 2023-05-11
Q4 2022 Unchanged 3,353,400 0 (0.0%) 0.17% $1,710,234 2023-02-09
Q3 2022 Unchanged 3,353,400 0 (0.0%) 0.27% $3,454,000 2022-11-10
Q2 2022 Added 3,353,400 +100,000 (3.1%) 0.35% $4,426,000 2022-08-12
Q1 2022 Added 3,253,400 +100,200 (3.2%) 0.29% $4,978,000 2022-05-11
Q4 2021 New 3,153,200 +3,153,200 (0.0%) 0.36% $5,833,000 2022-02-09
Institutional context

Who else reported the position

58 managers reported CARDIOL THERAPEUTICS INC for Q2 2026.

Manager Activity Shares Change % of reported 13F Reported value Tenure
MMCAP International Inc SPC This report Added 15,598,560 +246,243 1.4% $16,534,474 19 qtrs
Tejara Capital Ltd Reduced 5,113,822 -16,300 2.23% $5,420,651 15 qtrs
Ikarian Capital LLC Added 3,325,000 +600,000 0.38% $3,524,500 2 qtrs
BOOTHBAY FUND MANAGEMENT LLC Added 975,721 +180,840 0.01% $1,034,264 2 qtrs
CITADEL ADVISORS LLC Reduced 796,529 -23,375 < 0.01% $844,320 4 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 772,837 +543,031 < 0.01% $819,207 2 qtrs
TWO SIGMA INVESTMENTS LP Added 746,937 +212,726 < 0.01% $791,753 4 qtrs
INTEGRITY ALLIANCE LLC Reduced 388,492 -76,533 0.01% $411,802 3 qtrs
MORGAN STANLEY Added 355,030 +104,609 < 0.01% $376,332 9 qtrs
The Goldman Sachs Group Inc Added 333,900 +1,500 < 0.01% $353,934 15 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2026
Filed
August 14, 2026
Filing type
13F-HR
Position type
COM CL A

Voting authority reported

Sole
15,598,560
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.